Return to homepagePandemic Pact

Phase 1 Clinical Trial of CMS121, a Novel Therapeutic Candidate for Alzheimer's Disease

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3R01AG074447-01S1

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2021.0
    2023.0

  • Known Financial Commitments (USD)

    $210,130

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    . Pamela Maher

  • Research Location

    United States of America

  • Lead Research Institution

    VIROGENICS, INC.

  • Research Priority Alignment

    N/A

  • Research Category

    Secondary impacts of disease, response & control measures

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Abstract The parent grant for this application supports a Phase I clinical trial of CMS121, a small molecule that has shown efficacy in multiple mouse models of Alzheimer's Disease and which affords a different therapeutic approach for treatment of AD in humans. In this application we request supplemental funds to cover the costs of COVID-19 mitigation procedures and COVID-19 testing of trial subjects. These processes and associated costs were not necessary at the time of application due in large part to the rollout of highly effective vaccines and declining infections but have become essential now due to repeated surges in infections and the appearance of highly infectious variants of the virus. The mitigation and testing procedures are necessary to protect the clinical and non-clinical staff, as well as trial subjects at the clinical site from COVID-19 infection.